Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI

IVI Madrid662 enrolled

Overview

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Study Type

OBSERVATIONAL

Enrollment

662

Conditions

Infertility

Interventions

GanirelixDRUG

Ganirelix 0.25mg s.c every 24 h starting stimulation day 6

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * previous failed IUI cycle with premature luteinization Exclusion Criteria: * 39 years or older * not eligible for IUI (patent tubes, \> 3 million capacitated spermatozoa) * 4 previous IUI cycles

Locations (1)

IVI-Madrid

Madrid, Spain

Outcomes

Primary Outcomes

Pregnancy rate

Time frame: 2 weeks after intervention

Secondary Outcomes

premature luteinization

Time frame: at the time of intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.